SNM president promotes metabolic imaging for head and neck cancers

05/13/2010 |

Metabolic imaging can help advance diagnosis of head and neck cancers through improved visualization of metabolic pathways, hypoxia and tumor-specific receptors, SNM President Dr. Michael M. Graham said during the 2010 ASTRO Multidisciplinary Head and Neck Cancers Symposium. Agents showing promise for molecular imaging of metabolic pathways include FDG, 2-NBDG, FLT, 11C-acetate and amino acids, Graham said. Radiotracers for hypoxia imaging include FMISO and FAZA, and those for tumor-specific receptor imaging include MIBG, ProstaScint and Octrescan. "I think imaging with these agents is going to be huge, particularly as we advance the concept of personalized medicine," Graham said.

View Full Article in:

Published in Brief:

SmartBrief Job Listings for Health Care

Job Title Company Location
Director of Actuarial Services, Government Programs
Regional Director, Southeastern Region - State Affairs
America's Health Insurance Plans (AHIP)
Washington, DC
Counsel I – Clinical Contracts
Gilead Sciences
Foster City, CA
Associate - Food and Drug
Keller and Heckman LLP
Washington, DC
Vice President, Idaho Regional Director
Boise, ID